BUSINESSSTAT NEWS
STAT+: Hope for Kendall Square’s lab market
Sanofi halted a Phase 3 study of its drug riliprubart due to lack of efficacy, while Parabilis Medicines raised $670 million in a record biotech IPO. European countries face conflicts over drug-pricing policies amid budget strains and U.S. pressure.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more
- STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more
- STAT+: As the U.S. looks on, European countries feel growing pressure on drug prices
- STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more
- STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much more